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ABSTRACT
Purpose: The purpose of this study was to develop and evaluate nanoemulsion-based gel (nanogel) for 
transdermal delivery of ketoprofen. Among the various excipients tested, oleic acid, tween 80 and etha-
nol were selected as oil, surfactant, and co-surfactant respectively.
Methods: The nanoemulsions region was identified by constructing pseudo-ternary phase diagrams 
using aqueous phase titration. The prepared nanoemulsion was subjected to different thermodynam-
ic stability study and the nanoemulsion that passed thermodynamic stability tests were evaluated for 
viscosity, refractive index, droplet size, transmission electron microscopy, and ex-vivo permeation study 
using human cadaver skin.
Results: On the basis of evaluation C1 formulation, which consists of 3.09 % wt/wt of the oil phase, 
60.54 % wt/wt of Smix and 36.36 % wt/wt of distilled water were selected as an optimized formulation 
and were converted to nanogel using chitosan as a gelling agent. Nanogel was evaluated for ex-vivo and 
in vivo study. The nanogel showed a significant increase in the anti-inflammatory activity as compared 
to conventional gel.
Conclusion: In conclusion, nanogel could be a promising system to improve transdermal delivery of the 
ketoprofen.
Keywords: Transdermal delivery; ketoprofen; nanogel.
RESUMEN
Objetivo: El objetivo de este estudio fue desarrollar y evaluar un gel a base de nanoemulsión (nanogel) 
para el suministro transdérmico de ketoprofeno. Entre los diversos excipientes probados, se selecciona-
ron el ácido oleico, la mezcla de 80 y el etanol como aceite, surfactante y co-surfactante.
Métodos: La región de las nanoemulsiones se identificó mediante la construcción de diagramas de fase 
pseudoternarios utilizando la titulación de la fase acuosa. La nanoemulsión preparada se sometió a di-
ferentes estudios de estabilidad termodinámica y la nanoemulsión que pasó las pruebas de estabilidad 
termodinámica se evaluó para determinar la viscosidad, el índice de refracción, el tamaño de las gotitas, 
la microscopía electrónica de transmisión y el estudio de permeación ex-vivo utilizando piel de cadáver 
humano
Resultados: Sobre la base de la evaluación, la formulación de C1, que consiste en 3.09% peso / peso de 
la fase oleosa, 60.54% peso / peso de Smix y 36.36% peso / peso de agua destilada se seleccionaron como 
una formulación optimizada y se convirtieron a nanogel utilizando quitosano como Un agente gelifican-
te. Nanogel se evaluó para estudio ex-vivo e in vivo. El nanogel mostró un aumento significativo en la 
actividad antiinflamatoria en comparación con el gel convencional.
Conclusión: En conclusión, el nanogel podría ser un sistema prometedor para mejorar la administración 
transdérmica del ketoprofeno.
Palabras clave: Parto transdérmico; ketoprofeno; nanogel.
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INTRODUCTION
Ketoprofen, 2-(3-benzoylphenyl)-propionic acid is a 
non-steroidal anti-inflammatory agent widely used for the 
treatment of inflammatory diseases(1). In recent decades, the 
skin has become a well-known administration site for topi-
cal and systemic drug delivery. Transdermal delivery has a 
variety of advantages compared with the oral route. Main-
ly, it is used when the drug shows significant first-pass ef-
fect(2). Further, eliminating the problems associated with de-
creased gastrointestinal absorption. Therefore, transdermal 
administration is beneficial when a constant drug effect is 
desired(3). It is therefore desirable to develop a nanoformu-
lation system, which does not require the use of penetration 
enhancers to facilitate drug permeation through the skin. 
One of the most promising techniques for enhancement of 
transdermal permeation of drugs is the nanoemulsion tech-
niques(4). Nanoemulsion is defined as a dispersion consist-
ing of oil, surfactant, cosurfactant, an aqueous phase, which 
is a single optically isotropic and thermodynamically stable 
liquid solution with a droplet diameter usually in the range 
of 10- 200 nm(5). The nanoemulsion has a number of advan-
tages such as to increase drug solubility, thermodynamic 
stability, and transdermal permeation ability(6). The nano-
sized droplets leading to the enormous interfacial area as-
sociated with nanoemulsion would influence the transport 
properties of the drug, an important factor in sustained and 
targeted drug delivery(7)(8). In present work, chitosan is used 
as a gelling agent for ketoprofen nanoemulsion in order 
to retain the formulation on the skin for a longer period. 
Chitosan has been recognized for its variety of application 
including drug delivery, biomedical, and wound healing 
acceleration, anti-inflammatory (9)(10)(11)(12). The present study 
aims to formulate (nanogel) of ketoprofen for better per-
meation potential through the skin for pain management.
MATERIAL AND METHODS
Materials
Ketoprofen was a gift sample from Shreya Life sciences 
(Aurangabad, Maharashtra, India). Transcutol P, Lauro-
glycol 90, Peceol, Labrafil M 1944CS, Plurol Oleique CC 
497, Labrafac Lipophile WL 1349 were a gift sample from 
Gattefosse (Mumbai, India). Chitosan (85 % deacetylated) 
was purchased from Research Lab, Mumbai, India. Tween 
80, PEG 400, ethanol, acetic acid and oleic acid were pur-
chased from Merck (Mumbai, India). Deionised water was 
prepared by Ultra clear TWF UV system (SG Wasseraufbe-
reitung und Regenerierstation GmbH, Germany). All oth-
er chemicals used in the study were of analytical reagent 
grade.
METHODS
Solubility study
The solubility of the ketoprofen was determined in var-
ious excipients by taking excess amount of drug in 2 ml 
of each of the selected excipients in 5 ml capacity stopper 
vials. The vials were then kept at 25 ± 1.0°C in the orbital 
isothermal shaker (Lab enterprise, Bombay) for 72 hr to get 
equilibrium. The equilibrated samples were removed from 
the shaker and centrifuged at 2000 rpm for 10 min. The su-
pernatants were taken, filtered and analyzed for drug con-
tent using UV-Visible spectrophotometer (UV-1700, Phar-
maspec, Shimadzu Ltd, Japan) at λmax 260nm
(13).
Construction of pseudo-ternary phase diagrams
Based on the solubility studies, oleic acid was taken as the 
oil phase, tween 80 as surfactant and ethanol as a co-sur-
factant. Distilled water was used as an aqueous phase. 
Surfactant and co-surfactant (Smix) were mixed at different 
mass ratios (1:1, 1:2, 1:3). For each phase diagram, oil and 
Smix were mixed at a specific ratio (1:9 to 9:1) in different 
vials. Nine different combinations of oil and Smix, 1:9, 2:8, 
3:7, 4:6, 5:5, 6:4, 7:3, 8:2, 9:1 at each Smix (1:1, 1:2, 1:3) were 
made so that maximum ratios were covered for the study 
(Chemix Ternary Plot software). Slow titration with aque-
ous phase was performed for each mass ratio of oil and 
Smix and visual observations were made for transparent 
and easily flowable o/w nanoemulsions. The region of the 
nanoemulsion was marked on a pseudo-three-component 
phase diagram(14).
Selection and preparation of ketoprofen loaded nano-
emulsion formulation
From the phase diagram constructed, different formulas 
were selected from the nanoemulsion region so that keto-
profen could be incorporated into the oil phase. The drug 
was accurately weighted to represent 2.5% of the total 
weight of the formulation and added to the previous mix-
ture and stirred with a magnetic bar on the magnetic stirrer, 
at room temperature until the drug completely dissolved. 
The weighed amount of water then added drop-wise with 
continuous mixing(15).
Thermodynamic stability studies
The formulations selected from pseudo-ternary phase di-
agrams were further subjected to heating-cooling cycle, 
centrifugation test, and Freeze–thaw cycle(16)(17). The formu-
lations, which were stable, are selected for further charac-
terization.
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Viscosity
The viscosity of nanoemulsion was determined using 
Brookfield cone and plate rheometer (RS – CPS + Rheome-
ter, CP75*1) at 25 ± 0.5ºC (15).
Refractive index
The refractive index of placebo and nanoemulsion formu-
lation was determined using an Abbe’s type refractometer 
at 25 ± 0.5°C (18) (19).
Droplet size and PDI
Droplet size distribution and the polydispersity index of 
nanoemulsions were determined by using a Delsa Na-
no-C (Beckman Counter instruments) [18]. The sample of 
optimized nanoemulsion was suitably diluted with little 
amount of distilled water.
Transmission electron microscopy (TEM)
Morphology and structure of the nanoemulsion were stud-
ied using transmission electron microscopy (TEM) (Philips 
CM-10, USA) operating at 200kV and capable of point-to-
point resolution. The approximately the drop (50μl) of the 
nanoemulsion was suitably diluted with distilled water 
(1:100), filtered through 0.45μm filter paper and applied on 
the carbon-coated copper grid with 1% phosphotungstic 
acid. It was left for 30 sec for drying purpose. The dried 
coated grid was placed over the slide and covered with a 
coverslip for TEM observations.
Preparation of nanogel
The nanoemulsion C1 was selected as the optimized for-
mulations based on results obtained from the above char-
acterization. Further, it was converted into a chitosan nano-
gel formulation. The chitosan (1% w/w) was used; it was 
initially dissolved in a solution of acetic acid 0.5% v/w. The 
10 ml of optimized C1 formulation was slowly added to 
the viscous dispersion of chitosan (1% w/w) with continu-
ous stirring on a magnetic stirrer (Remi Mechanical Stirrer, 
Mumbai, India) to obtain a completely homogenous mix-
ture. The prepared nanogel formulation was stored in a 
sealed container(20).
Ex-vivo permeation study
Excised human cadaver skin (HCS) from the abdomen was 
obtained from Govt. Medical College, Aurangabad. The 
skin preparation was done for ex-vivo permeation study 
(21). Skin penetration studies were carried out by using a 
modified diffusion cell. The cell had a diffusion surface 
area of 4.9 cm2 and a volume of 13 ml in the receptor com-
partment. HCS was mounted horizontally on the receiver 
compartment. Initially, the donor compartment was emp-
ty and the receiver chamber was filled with pH 7.4 phos-
phate buffered solution. The receptor fluid was constantly 
stirred with mentioning constant temperature at 37 ± 0.50C. 
The buffer mixture solution was replaced with fresh buffer 
every 0.5 h to stabilize the skin. It was found that the receiv-
er fluid showed negligible peak absorption after 5 hr and 
beyond, indicating complete stabilization of the skin. After 
complete stabilization of the skin, the 5 ml nanoemulsion 
and 0.5 gm gel were placed into each donor compartment. 
Samples were withdrawn at one hour intervals up to 10 h 
and analyzed for drug content by using UV-Visible spectro-
photometer (UV-1700, Pharmaspec, Shimadzu Ltd, Japan) 
at λmax 260 nm and permeability parameters such as perme-
ability coefficient (Kp) was calculated by dividing the flux 
(Jss) by initial concentration in the donor compartment and 
flux was obtain from straight line by plotting the cumula-
tive amount of ketoprofen permeated per unit area of skin 
versus time at steady state condition (20).
In vivo study
Protocol to perform the anti-inflammatory activity of 
optimized formulation on the animal was approved by 
the Institutional animal ethical committee (IAEC) of Dr. 
VVPF’s College of Pharmacy, Ahmednagar, India (COPH/
IAEC/2017/Protocol No.10). The anti-inflammatory ac-
tivity of ketoprofen loaded nanoemulsion-based gel was 
evaluated using carrageenan induced hind paw edema 
method. The healthy male rats, weighing 120-250g, were 
randomly divided into three groups each containing six 
rats. The rats were given free access to water and food. The 
rats were kept under observation for 24 h. The backsides of 
rats were shaved 12h before starting the experiment. The 
optimized nanogel formulation for the first group and C1 
for second group were applied on the shaved back of all 
animals (except third control group) half an hour before 
subplantor injection of carrageenan in the right paw of rats. 
Paw edema was induced by injecting 0.1 ml of a 1%w/v 
homogeneous suspension of carrageenan in double dis-
tilled water(22). The volume of paw edema was measured 
immediately (0 h) and at 1hr interval up to 5hr after injec-
tion using a plethysmometer. The amount of paw edema 
swelling was determined time-to-time and expressed as 
percent edema relative to the initial (0 h) hind paw volume. 
The mean value of the percentage was determined for each 
time interval. Percentage inhibition of edema produced by 
each formulation treated group was calculated against the 
respective control group using the following formula.
The percent swelling of the paw was determined by using 
the following equation,
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Where, V is the paw volume of the carrageenan injection 
after 8h, and Vi is the initial paw volume. The average paw 
swelling in the group of the drug-treated rats was com-
pared with control rats and the percent of inhibition of the 
oedema formation was determined using following equa-
tion(23),
Stability studies
The stability study was performed accordingly to ICH 
guideline by storing the optimized nanogel formulation in 
transparent seal vial at 40±2°C / 75%RH in stability cham-
ber (Lab- Care, Mumbai) for six months. The samples were 
withdrawn after six months and analyzed for drug content 
and viscosity(24).
RESULTS AND DISCUSSION
Solubility study
In the solubility study, it was observed that the maximum 
solubility of ketoprofen was found in oleic acid as com-
pared to the other oils. Moreover, oleic acid also acts as a 
penetration enhancer for transdermal delivery. Transient 
negative interfacial tension and fluid interfacial film are 
rarely achieved by the use of single surfactant; therefore 
usually, the addition of a co-surfactant is necessary [17]. The 
co-surfactant selected for the study was ethanol which 
shows higher drug solubility, also acts as a permeation en-
hancer and has an HLB value of 4.2. The solubility of keto-
profen in different excipients is shown in Fig.1.
Figure 1. A. Solubility of ketoprofen in oils, surfactants, and 
co-surfactants and B. Pseudo-ternary phase diagrams
Pseudo-ternary phase diagrams
Pseudo-ternary phase diagrams (PTD) as shown in Figure 
1 were prepared separately for each Smix ratio i.e. 1:1, 1:2 
and 1:3 so that o/w nanoemulsion region can be identified 
and optimized for further study. The nanoemulsion region 
was identified and shaded on PTD for further optimization. 
Pseudo-ternary phase system with tween80: ethanol (1:3) 
exhibited a maximum area for nanoemulsion formation. 
The wider region indicated better nanoemulsifying effi-
ciency of the developed formulation and better interaction 
among oil phase, Smix, an aqueous phase. In Fig.1a, the Smix 
ratio 1:1 has a very low nanoemulsion area. The maximum 
concentration of oil that could be solubilized in the phase 
diagram was only 7.73% wt/wt using 67.67 % wt/wt of 
Smix. As the co-surfactant concentration was increased in 
the Smix ratio 1:2, a slight higher nanoemulsion region was 
observed, perhaps because of further reduction of the inter-
facial tension. The maximum concentration of oil that could 
be solubilized in the phase diagram was 7.40 % wt/wt using 
64.73% wt/wt of Smix. As we further increased co-surfactant 
concentration, Smix 1:3, the nanoemulsion region increased 
as compared with the region in 1:1 and 1:2. The maximum 
concentration of oil that could be solubilized by this ratio 
was 7.2% wt/wt using 63.09% wt/wt of Smix. The formula-
tions which are clear and transparent and easily flowable 
are selected for further thermodynamic stability study.
Thermodynamic stability of nanoemulsions
The selected formulations were passing the thermodynam-
ic stability tests. Therefore, it revealed that developed for-
mulations are physically and chemically stable. The com-
position of selected formulations is given in Table 1.
Table 1. Composition of the selected nanoemulsion
Formu-
lation
Oleic 
acid 
(%w/w)
Smix 
(%w/w)
Water 
(%w/w)
Ratio 
of S/
Co-s
Keto-
profen 
(%w/w)
A1 3.49 68.51 27.98 01:01 2.5
A2 7.73 67.67 24.57 01:01 2.5
B1 3.28 64.28 32.43 01:02 2.5
B2 7.40 64.73 27.86 01:02 2.5
C1 3.09 60.54 36.36 01:03 2.5
C2 7.2 63.09 29.69 01:03 2.5
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Viscosity
The viscosity study results revealed that viscosity increase 
with an increase in the oil content shown in Fig.2 A. The for-
mulation A1-A2, the oil concentration was increased from 
3.49 % w/w to 7.73 % w/w, and at the same time water 
concentration decrease from 27.98% w/w to 24.57 % w/w, 
which leads to the increase in the viscosity from 34.0 ± 2.40 
cp to 52.20 ± 3.70 cp. The formulation B1-B2, the oil concen-
tration was increased from 3.28 % w/w to 7.40 % w/w, an 
increase in the viscosity from 38.10± 4.62 cp to 62.50± 5.45cp 
was observed. The same observation was obtained in for-
mulation C1-C2. The viscosity of the C1 was found to be 
very low (25.20± 2.74 cp) as compared to other formulation. 
This might be due to the presence of low concentration of 
oil in the formulation and more water content. The same 
observation was reported that low oil content leads to low-
er viscosity values (25).
Refractive index (RI)
RI is an optical property of nanoemulsion and which can be 
used to indicate the isotropic nature. When the refractive 
index values of all formulation were compared with those 
of the placebo, it was found that there was no significant 
difference between the values of RI of water as shown in 
Table 2. The result revealed that the developed formulation 
is isotropic in nature and also no interaction between nano-
emulsion components.
Table 2. Droplet size, PDI and Zeta potential, viscosity, flux and refractive index of formulations
Formulation 
code
Droplet 
size (nm)
PDI
Zeta poten-
tial (mV)
Permeability 
Coefficient (Kp)
Flux (JSS) (µg/
cm2/hr)
Refractive index
Placebo Formulation
A1 63.8 ± 4.04 0.355 -7.55 ± 0.02 0.002062 24.75± 5.20 1. 389 1.399 ± 0.02
A2 132.0 ± 2.4 0.280 -21.90 ± 2.63 0.000920 11.05± 3.12 1.390 1.395 ± 0.01
B1 57.2 ± 3.01 0.346 -12.92 ± 0.4 0.00248 29.77± 4.25 1.391 1.451 ± 0.02
B2 98.3 ± 5.2 0.387 -25.36 ± 1.20 0.001157 13.89± 2.15 1.393 1.399 ± 0.02
C1 56.5 ± 4.2 0.270 -31.87 ± 0.01 0.002972 35.67± 3.28 1.390 1.389 ± 0.01
C2 81.7 ± 1.02 0.377 -13.93 ± 0.12 0.001560 18.72 ± 3.10 1.387 1.386 ± 0.02
Control 0.000497 5.97 ± 3.10
Nanogel 0.004170 50.12 ± 5.12*
Conventional gel 0.002120 25.45± 7.24
All values are expressed as mean ± SD, n = 3. * P<0.05 compared to C1 and conventional gel
Droplet size and Polydispersity index (PDI)
The mean droplet size of the formulations decreased as the 
concentration of oil decreased the droplet size of the for-
mulations containing different Smix ratio decreased as the 
surfactant to co-surfactant ratio increased from 1:1 to 1:3. 
The mean droplet size of C1 formulation with 3.09 % oil 
having 1:3 Smix was smaller (56.5 ± 4.2 nm) as compared to 
other formulations (Table 2, Fig 2A1). This might be due to 
the low oil content in C1 formulation, which leads to the 
smaller droplet size. The observation was similar to previ-
ously reported that the less oil content leads to a decrease 
in the droplet size(25). The PDI of formulation C1 was lower 
(0.27) as compared to other formulations. The lower values 
of polydispersity values observed for all the formulations 
indicated uniformity of droplet size within each formula-
tion.
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Figure 2. A. Viscosity values of all formulation in triplicate. A1. 
Particle size distribution of C1 formulation and B2. TEM image of 
C1 formulation
Zeta Potential
Zeta potential values of all the nanoemulsion formulations 
are given in Table 2. Zeta potential values of the formula-
tions were found to be in the range - 31.87 to - 7.55 mV. 
Among the formulations studied C1 showed the highest 
zeta potential shown in Table 2. Negative values of the 
zeta potential of the formulations indicated that the formu-
lations were negatively charged and higher value of zeta 
potential of the C1 formulation signified stability of the 
system.
Transmission electron microscopy (TEM)
The results of TEM analysis of nanoemulsion C1 corre-
lates with droplet size obtained by PCS and confirmed that 
droplets of C1 nanoemulsion formulation were spherical in 
shape and finely distributed with micron size range within 
100 nm as shown in Figure 2 B2.
Ex-vivo permeation study
The results of ex-vivo permeation parameters of selected 
nanoemulsion and control formulation (drug suspension) 
are illustrated in Table 2. The C1 formulation showed the 
highest flux (35.67± 3.28 μg/cm2/hr) and significant as 
compared to other formulation. This might be due to the 
smaller droplet size which enhanced the permeation of 
drug through the skin. The results revealed that smaller 
the droplet size of formulation maximum permeation is ob-
served. Whereas, the A2 formulation had a larger globule 
size (132.0 ± 2.4nm), showed less flux value (11.05± 3.12 μg/
cm2/hr) compared to other formulation. The ex-vivo skin 
permeation profile of all formulation is shown in Figure 3.
Figure 3. Ex-vivo skin permeation profile of all formulation 
through human cadaver skin
Evaluation of nanogel formulations
Ex-vivo permeation study
The ex-vivo skin permeation results of C1, nanogel, and 
conventional gel (marketed gel) are shown in Table 2. The 
nanogel showed the highest flux (50.12 ± 5.12) compared to 
conventional gel and C1 formulation.
In vivo studies:
Carrageenan induced rat paw edema has been considered 
as a useful model for studying the anti-inflammatory effect 
of the drug in rats(26). The anti-inflammatory activity out-
come of formulations is reported in Table 3, where the val-
ue of nanogel indicated a significant difference (P<0.05) as 
compared to nanoemulsion. The anti-inflammatory activity 
was found to be 74.0 % after 8 h, which concludes that na-
nogel performed the greater activity as compared to control 
107Ars Pharm. 2019; 60(2): 101-108
Formulación y evaluación de ketoprofeno cargado de nanogel de quitosán para el manejo del dolor: estudio ex vivo e in vivo
group and nanoemulsion. The maximum anti-inflammato-
ry effects of the nanogel formulation could be due to the 
maximum concentration of ketoprofen available at target 
side and due to nanosize leads to enhance permeation of 
drug through the skin.
Table 3. Anti- inflammatory activity of formulations in rats
Formulation Percent swelling Percent inhibition
Control 48.25± 6.25 ----
Nanogel 12.55± 4.56 74.0*
C1 25.60 ± 4.89 47.00
Value are expressed as mean ± SD, * P<0.05 compared to C1 
and control group.
Stability study
Stability study of the nanogel was carried out for 3 months 
and no significant change in the values was found in drug 
content and viscosity as shown in Table 4. This shows that 
the ketoprofen nanoemulsion nanogel is stable. The stabil-
ity may be due to the smaller droplet size of nanoemulsion 
which is less prone to undergo coalescence. The observa-
tion is similar to the previously reported(27) that smaller 
droplets are less susceptible to fluctuations which reduced 
creaming and coalescence, explaining the high stability of 
nanoemulsions.
Table 4. Stability study of the nanogel formulation
Parameter 0 day After 3 months
Viscosity 480.20± 2.74 490.40± 3.55
Drug content 99.85± 0.25 99.75 ± 0.15
*All values are expressed as mean ± SD, n = 3.
CONCLUSION
The study represents the formulation of ketoprofen nano-
emulsion loaded gel for transdermal delivery. Based on the 
globule size (228.8 nm), PDI, zeta potential, flux (10.5±2.6 
μg/cm2/hr) formulation C1 was selected as an optimized 
formulation and converted into gel formulation which 
gives desirable ex-vivo release profile. The in-vivo study 
revealed a significant increase in percent inhibition (74.0 
% for 8 h) of nanogel formulation as compared (P<0.05) 
to conventional gel. Overall, the results indicate that de-
veloped nanogel formulation can be successfully used for 
transdermal delivery of ketoprofen in pain management.
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